How should we regulate genome editing for pharmaceutical applications?

Genome editing technologies are not only having a game-changing effect on research. They also have the potential to transform health care by curing diseases for which there are currently no or no satisfactory therapies available.

In particular with the emergence of novel gene editing technologies such as CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) in the pharmaceutical arena the question arises how to best regulate these technologies.

Read more from Dr. Diane Seimetz, one of the lecturers in the GBS Pharma MBA Strategic Management & Corporate Development module. 

Dr. Diane Seimetz holds a degree in pharmaceutical sciences and completed her PhD at the German Cancer Research Center and the Johns Hopkins University in Baltimore (USA). She also holds a Master’s Degree in Drug Regulatory Affairs and is an experienced drug development and regulatory expert with proven track record bringing first in class products from idea to approval. Dr. Seimetz has over 19 years of global drug development, regulatory affairs and partnering experience in the pharmaceutical industry.